Krystal Biotech, Inc. (NASDAQ:KRYS) is S Squared Technology LLC's 3rd Largest Position

S Squared Technology LLC increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 26.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 95,215 shares of the company's stock after purchasing an additional 20,000 shares during the quarter. Krystal Biotech comprises about 6.2% of S Squared Technology LLC's holdings, making the stock its 3rd largest position. S Squared Technology LLC owned 0.33% of Krystal Biotech worth $14,916,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in Krystal Biotech by 15.1% in the third quarter. Wellington Management Group LLP now owns 12,680 shares of the company's stock worth $2,308,000 after acquiring an additional 1,660 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock worth $107,714,000 after acquiring an additional 11,411 shares during the last quarter. Teachers Retirement System of The State of Kentucky boosted its stake in shares of Krystal Biotech by 198.2% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company's stock valued at $1,640,000 after purchasing an additional 5,989 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Krystal Biotech in the 3rd quarter worth $40,000. Finally, Franklin Resources Inc. lifted its stake in Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup upped their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Finally, Chardan Capital boosted their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $220.00.

Krystal Biotech Trading Up 2.0 %

KRYS traded up $3.16 during trading on Tuesday, reaching $165.07. The stock had a trading volume of 30,695 shares, compared to its average volume of 281,750. The stock's 50 day moving average is $175.31 and its two-hundred day moving average is $171.72. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34. The company has a market capitalization of $4.77 billion, a price-to-earnings ratio of 55.14 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm's quarterly revenue was up 116.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.30 EPS. On average, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).